Australia's most trusted
source of pharma news
Tuesday, 02 December 2025
Posted 1 December 2025 PM
The TGA has 'aligned' product warnings across high-profile diabetes and obesity drugs to ensure consistent information regarding the potential risk of suicidal thoughts or behaviours.
The drugs impacted by the TGA decision cover the GLP-1 RA class of medicines which includes Novo Nordisk's Ozempic, Wegovy and Saxenda and Eli Lilly's Trulicty and Mounjaro.

Please click the button to indicate that the printout of this article is for your personal use only and not for any type of redistribution.
Redistribution of the whole or part of Pharma in Focus by any means is a breach of copyright law.